Thank you, Operator. Welcome, and thank you all for joining us today for a review of Syndax's second quarter 2023 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the Company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Dr. Neil Gallagher, President and Head of R&D and Keith Goldan, Chief Financial Officer. Also joining us on the call today for the question-and-answer session are Dr. Peter Ordentlich, Chief Scien ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other Ju ...

Peter Lawson - Barclays Justin Zelin - BTIG Sharon Klahre Michael Metzger We also welcome Kevin McManus to the company, as our new Chief People Officer. We look forward to benefiting from his extensive experience and vision in building our organization and culture. We have several additional trials ongoing designed to expand the potential of revumenib beyond used as a monotherapy agent in patients with relapsed/refractory acute leukemias including combinations with standardof-care regimens to treat these fo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other J ...

First one just on the pool KMT2A cohort. Do you anticipate that the efficacy will be presented just for the pooled cohort on the label? Or could there also be a breakdown of AML and ALL on the label? Michael Metzger Yes, Joel, great question. I think that was sort of alluded to or part of another question that was asked earlier. The strategy for pooling is that the -- we'll be presenting a total number of patients and they'll be analyzed. I think the -- of course, the agency will look at all the subsets, an ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 2834 32-0162505 (State or Other J ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 CORPORATE PRESENTATION | JANUARY 2023 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forwar ...

Syndax 珍 | --- | --- | |-------|--------------------------| | | Dose: 1mg/kg q2wk | | | n= 23 patients | | | Primary endpoint: ORR* | | | (2014 NIH GVHD criteria) | KPS at enrollment, median (range) 80 (60, 100) 80 (60, 90) 80 (60, 100) • No evidence of end-organ damage, myositis/pancreatitis with enzyme elevations 52% FIBROSIS CSF-1R Circulating Monocyte CSF-1 Circulating Monocyte Macrophage Tissue Fibroblasts Collagen CSF-1R CSF-1R CSF-1 Circulating Monocyte Blood vessel CSF-1R M2 macrophage 17 Myeloablat ...

Revumenib Data Update Call with Dr. Ghayas Issa and Dr. Eytan Stein Syndax 參 DECEMBER 11TH, 2022 – ASH ANNUAL MEETING Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All st ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 3Q22 INVESTOR PRESENTATION – NOVEMBER 3, 2022 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identif ...